There is, however, ongoing effort in UK primary care to optimise monitoring and management across individual’s needs and, therefore, extra consultations may not be needed.33 Finally, this study only included patients with hypertension and previous CVD and focused on blood-pressure lowering and statin treatments; future investigations could be extended to optimising statin treatment for primary CVD prevention or indeed consider the use of novel interventions, such as PCSK9 inhibitors, to further reduce population CVD risks.34 This evidence concerns the gene PCSK9 and Hypertension.